Erciyes University Medical Faculty, Department of Nephrology, Kayseri, Turkey.
Ren Fail. 2010 Jan;32(2):179-84. doi: 10.3109/08860220903491224.
Aminoglycosides have been used in the treatment of CAPD peritonitis despite their potential risk for ototoxicity. The ototoxicity risk of intraperitoneally administered aminoglycosides has been investigated by a number of studies. However, their results are somewhat conflicting. The aim of the present study was to examine the frequency of hearing loss and the correlation between the repeated doses of aminoglycosides and hearing loss in CAPD peritonitis therapy.
Hearing functions of the CAPD patients who had developed peritonitis and had been treated with various antibiotics including aminoglycosides were compared with those CAPD patients who had never developed peritonitis. Threshold values for hearing were determined through "pure tone audiometry" measurements.
Hearing threshold levels of the patients with history of peritonitis were found to be significantly higher in both lower [pure tone averages - 1 (PTA-1)] and higher [pure tone averages - 2 (PTA-2)] frequencies, when compared to the ones with no history of peritonitis (p values were 0.001 and 0.007, respectively).
The present study showed that intraperitoneal aminoglycoside administration in CAPD patients is associated with the development of hearing loss. The severity of hearing loss may range from mild hearing loss to profound deafness. A remarkable correlation exists between the severity of the hearing loss and the repeated and total aminoglycoside dose received.
尽管氨基糖苷类药物有耳毒性风险，但仍被用于治疗 CAPD 腹膜炎。已有多项研究调查了腹腔内给予氨基糖苷类药物的耳毒性风险。然而，其结果有些相互矛盾。本研究旨在探讨 CAPD 腹膜炎治疗中氨基糖苷类药物重复剂量与听力损失之间的相关性，并检测听力损失的发生频率。
通过“纯音测听”测量，比较发生过腹膜炎且接受过包括氨基糖苷类在内的各种抗生素治疗的 CAPD 患者与从未发生过腹膜炎的 CAPD 患者的听力功能。
与无腹膜炎病史的患者相比，有腹膜炎病史的患者的听力阈值在低频[纯音平均听力值-1（PTA-1）]和高频[纯音平均听力值-2（PTA-2）]时均显著升高（p 值分别为 0.001 和 0.007）。
本研究表明，腹腔内给予 CAPD 患者氨基糖苷类药物与听力损失的发生有关。听力损失的严重程度可从轻度听力损失到重度耳聋不等。听力损失的严重程度与接受的氨基糖苷类药物重复剂量和总剂量之间存在显著相关性。
